Patrick O'Brien, COO and General Counsel at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 56,080 shares at $31.83 ($1.9M) on 2024-01-03, disclosed to the SEC on 2024-01-05.
Scheduled sale ($1.9M) by COO and General Counsel under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $31.83 | 3,849 | $123K | 6.4% |
| 2 | $31.83 | 3,849 | $123K | 6.4% |
| 3 | $32.52 | 2,800 | $91K | 4.7% |
| 4 | $32.52 | 2,800 | $91K | 4.7% |
| 5 | $32.65 | 1,700 | $56K | 2.9% |
| 6 | $33.41 | 400 |
| $13K |
| 0.7% |
| 7 | $32.63 | 1,600 | $52K | 2.7% |
| 8 | $32.63 | 1,600 | $52K | 2.7% |
| 9 | $33.99 | 1,900 | $65K | 3.4% |
| 10 | $33.99 | 1,900 | $65K | 3.4% |
| 11 | $34.99 | 8,200 | $287K | 14.9% |
| 12 | $35.65 | 12,741 | $454K | 23.6% |
| 13 | $35.65 | 12,741 | $454K | 23.6% |
| Total | $34.32 avg | 56,080 | $1.9M | 100% |
| Filing → |
| GLRE | SELL | 2025-05-14 | $267K | — | Filing → |
| ARWR | SELL | 2025-01-07 | $1.3M | — | Filing → |
| ARWR | SELL | 2023-01-06 | $280K | — | Filing → |